000825718 001__ 825718
000825718 005__ 20210129225416.0
000825718 0247_ $$2doi$$a10.1055/s-0035-1564177
000825718 0247_ $$2ISSN$$a0723-7065
000825718 0247_ $$2ISSN$$a1439-5800
000825718 037__ $$aFZJ-2017-00035
000825718 082__ $$a610
000825718 1001_ $$0P:(DE-HGF)0$$aHutterer, M.$$b0
000825718 245__ $$aPitfalls in der [18F]-FET-PET-Diagnostik von Hirntumoren
000825718 260__ $$aStuttgart$$bThieme$$c2015
000825718 3367_ $$2DRIVER$$aarticle
000825718 3367_ $$2DataCite$$aOutput Types/Journal article
000825718 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1483600476_4023
000825718 3367_ $$2BibTeX$$aARTICLE
000825718 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000825718 3367_ $$00$$2EndNote$$aJournal Article
000825718 520__ $$aIn clinical neuro-oncology structural magnetic resonance imaging (MRI) is currently the investigation of choice for diagnosing brain tumors. In many situations, however, the capacity of MRI identifying non-enhancing tumor or differentiating neoplastic tissue from unspecific treatment-related changes is limited.In the last years positron emission tomography (PET) using radiolabeled amino acids such as O-(2-[18F]-Fluoroethyl)-L-tyrosine (FET) and [11C]-methionine (MET) in combination with MRI has shown a great potential for a more accurate diagnosis of gliomas. The decisive advantage of amino acid PET is a tumor-specific tracer uptake independent from the blood-brain-barrier permeability. In the diagnostics of primary brain tumors the amino acid PET is able to describe the localization, extent and heterogeneity of the metabolic active tumor, which can be used for improved targeting of biopsy as well as planning of resection and radiotherapy by better visualization of tumor margins. Furthermore, following chemo-/radiotherapy amino acid PET can be used for distinguishing tumor recurrence from pseudoprogression and tumor response from pseudoresponse during antiangiogenic treatment.The main advantage of FET compared to MET is the longer half-life of the [18F]-label, which allows a distribution on a wide clinical scale. In addition, FET uptake appears to be more specific for tumor tissue, because there is a higher uptake of MET in inflammatory cells and tissues.Due to the rapidly growing importance and regular use of amino acid PET in many neuro-oncology centers the aim of this review is to highlight the “pitfalls” especially of FET PET diagnostics of brain tumors. The differential diagnosis of newly diagnosed solitary cerebral lesions with or without (circular) contrast enhancement on MRI includes different types of malignant brain tumors, as well as various benign, non-neoplastic lesions such as inflammatory, ischemic, hemorrhagic or traumatic lesions.
000825718 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000825718 588__ $$aDataset connected to CrossRef
000825718 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, N.$$b1$$ufzj
000825718 7001_ $$0P:(DE-HGF)0$$aHau, P.$$b2
000825718 7001_ $$0P:(DE-Juel1)131777$$aLangen, K.-J.$$b3$$ufzj
000825718 773__ $$0PERI:(DE-600)2092413-6$$a10.1055/s-0035-1564177$$gVol. 38, no. 04, p. 295 - 303$$n04$$p295 - 303$$tDer @Nuklearmediziner$$v38$$x0723-7065$$y2015
000825718 909CO $$ooai:juser.fz-juelich.de:825718$$pVDB
000825718 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b1$$kFZJ
000825718 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b3$$kFZJ
000825718 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000825718 9141_ $$y2016
000825718 915__ $$0StatID:(DE-HGF)0020$$2StatID$$aNo Peer Review
000825718 915__ $$0StatID:(DE-HGF)0550$$2StatID$$aNo Authors Fulltext
000825718 920__ $$lyes
000825718 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000825718 980__ $$ajournal
000825718 980__ $$aVDB
000825718 980__ $$aUNRESTRICTED
000825718 980__ $$aI:(DE-Juel1)INM-3-20090406